Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

agulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... 24, 2014  Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... compared with the prior year. Reported sales increased 5% ... Net earnings per diluted share as reported (EPS) were ... 2013. Adjusted EPS was $2.57, an increase of 9% ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... (Nasdaq: BIOD ) today reported financial results for the ... Year 2011 Financial Results Biodel reported a net loss ... or $0.20 per share, compared to a net loss of $11.1 ... prior year. Research and development expenses were $5.5 ...
... CFN ), a leading, global medical technology company, ... Dec. 31, 2010. "Our strong second quarter results ... Infection Prevention businesses, and a benefit from a lower tax ... had announced in November 2010 his plans to retire. On ...
Cached Medicine Technology:Biodel Reports First Quarter Fiscal Year 2011 Financial Results 2Biodel Reports First Quarter Fiscal Year 2011 Financial Results 3Biodel Reports First Quarter Fiscal Year 2011 Financial Results 4Biodel Reports First Quarter Fiscal Year 2011 Financial Results 5Biodel Reports First Quarter Fiscal Year 2011 Financial Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 2CareFusion Reports Second Quarter Fiscal 2011 Results 3CareFusion Reports Second Quarter Fiscal 2011 Results 4CareFusion Reports Second Quarter Fiscal 2011 Results 5CareFusion Reports Second Quarter Fiscal 2011 Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 7CareFusion Reports Second Quarter Fiscal 2011 Results 8CareFusion Reports Second Quarter Fiscal 2011 Results 9CareFusion Reports Second Quarter Fiscal 2011 Results 10CareFusion Reports Second Quarter Fiscal 2011 Results 11CareFusion Reports Second Quarter Fiscal 2011 Results 12CareFusion Reports Second Quarter Fiscal 2011 Results 13CareFusion Reports Second Quarter Fiscal 2011 Results 14CareFusion Reports Second Quarter Fiscal 2011 Results 15
(Date:7/25/2014)... The report, "Wireless Gigabit (WiGig) Market ... Alliance, Access Points, Routers, Residential Gateways, Backhaul Equipment) ... Analysis (2014 - 2019)," provides a comprehensive market ... by WiGig enabled products, and regions. The report ... WiGig market, and provides the quantitative (market size ...
(Date:7/25/2014)... 2014 Garth Brooks Chicago tickets go ... Arena in Rosemont. Garth Brooks was one of the leaders ... first single in 1989. Since "Much Too Young (To Feel This ... from the Tulsa, Okl. native and in the years that he ... back on a stage and in the recording studio. Between 2001 ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... New York, New York (PRWEB) July 25, 2014 ... reviews JDRF’s revenue and spending during fiscal year 2013 (July ... government’s National Institutes of Health (NIH), the JDRF is the ... world. It has global reach and relationships with most ... better positioned to deliver a cure for type 1 diabetes ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Project Ninety ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , For more than four decades, Project ... Area community through its residential alcohol and substance abuse ... on Project Ninety's humble idea and how it has ...
Breaking Medicine News(10 mins):Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3
... ... a leading provider of information-based technology services to the health care industry, ... Texas in addition to its services that are provided to physicians throughout ... New Hampshire and is owned by Medical Protective, part of the Berkshire ...
... NJ A recent study published in International ... extract from the bark of the French maritime pine ... associated with various health problems. Dr. Raffaella Canali ... in Rome, Italy, found that Pycnogenol inhibits the generation ...
... , , PORTLAND, Ore., ... reform is the power of simple questions that people can ask each ... , To spark this effort, Regence BlueCross ... to inspire debate, discussion, and ultimately engagement and action by consumers. As ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... HARRISBURG, Pa., July 15 The Department of Environmental Protection and ... day for June 16 in the Philadelphia region. , ... will be code ORANGE for ozone in the region, which includes ... , The U.S. Environmental Protection Agency,s standardized ...
... , PITTSBURGH, Jul. 15 Leo W. Gerard, President ... to the U.S. House of Representatives, health care reform bill. , ... ) , , ... of efforts by the U.S. House leadership to fix our broken ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:Study demonstrates the anti-inflammatory properties of pine bark extract 2Health News:Regence Launches Effort to Further Health Care Debate 2Health News:Regence Launches Effort to Further Health Care Debate 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Air Quality Action Day Forecast for July 16 in Philadelphia Region 2Health News:Statement by USW President Leo W. Gerard on U.S. House Health Care Reform Bill 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: